血清降钙素原、白蛋白、可溶性髓样细胞触发受体-1对脓毒症患儿的临床诊断价值

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (648 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical value of serum procalcitonin (PCT), albumin (Alb) and soluble myeloid cell triggering receptor-1 (sTREM-1) in the diagnosis of children with sepsis. Methods From October 2015 to August 2017, 140 children with sepsis (sepsis group) and 60 cases of non-infectious children with systemic inflammatory response syndrome (control group) in Hu′nan Provincial Maternal and Child Health Care Hospital were selected as the study objects. Levels of serum PCT, Alb, and sTREM-1 were compared between two groups, and according to the condition of illness, children of the sepsis group were divided into general sepsis group (79 cases), severe sepsis group (43 cases) and septic shock group (18 cases) for subgroup analysis. The value of serum PCT, Alb, and sTREM-1 alone or in combination in the diagnosis of sepsis was analyzed by using the subjects′ work curve. Results The levels of serum PCT and sTREM-1 of the sepsis group were significantly higher than those of the control group (P < 0.05); level of serum Alb and PCIS score of the sepsis group were significantly lower than those of the control group (P < 0.05); the differences of serum PCT, sTREM-1 in general sepsis group, severe sepsis group and septic shock group were statistically significant (P < 0.05), without gradual increasing trend; the differences of serum Alb, PCIS score among groups were statistically significant (P < 0.05), without gradual decreasing trend. The sensitivity, specificity and AUC value of PCT+Alb+sTREM-1 were 91.96%, 95.72% and 0.956 respectively in the diagnosis of children with sepsis and inflammatory response syndrome. Conclusion PCT+Alb+sTREM-1 combined diagnosis has higher clinical value in children with sepsis.

Key words： Procalcitonin Albumin Soluble myeloid cell triggering receptor -1 Sepsis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Jing YANG Xiangfeng MENG Xianmei GUO Ru LI Fang

Cite this article:

ZHANG Jing YANG Xiangfeng MENG Xianmei GUO Ru LI Fang. Clinical diagnostic value of serum procalcitonin, albumin and soluble myeloid cell trigger receptor-1 in children with sepsis[J]. 中国医药导报, 2018, 15(24): 107-110.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I24/107

[1] Plunkett A，Tong J. Sepsis in children [J]. BMJ，2015，350（5）：3017-3021.
[2] Thompson GC，Macias CG. Recognition and Management of Sepsis in Children：Practice Patterns in the Emergency Department [J]. J Emerg Med，2015，49（4）：391-399.
[3] 高东培，李凤艳，谢垒，等.脓毒症患儿血清可溶性髓样细胞触发受体-1、可溶性尿激酶型纤溶酶原激活物受体变化的意义[J].中华实用儿科临床杂志，2015，30（6）：433-437.
[4] 李霞，何攀文，卢忠心，等.血清降钙素原与和肽素联合检测在脓毒血症患者病情监测和预后评估中的临床价值[J].中华实验外科杂志，2015，32（12）：2989-2991.
[5] 胡检生，谢慧君，谢基华，等.小儿脓毒症生物标志物风险模型在脓毒症相关多器官功能衰竭患儿诊治中的应用[J].中国急救医学，2017，37（6）：497-501.
[6] 中华医学会重症医学分会.中国严重脓毒症/脓毒性休克治疗指南（2014）[J].中华内科杂志，2015，54（6）：401-426.
[7] 朱满意，韦正祥.脾多肽对急性脑出血致全身炎症反应综合征的疗效观察[J].浙江医学，2017，39（7）：562-564.
[8] Randolph AG，Mcculloh RJ. Pediatric sepsis [J]. Virulence，2013，5（1）：179-189.
[9] Matics TJ，Sanchez-Pinto LN. Adaptation and Validation of a Pediatric Sequential Organ Failure Assessment Score and Evaluation of the Sepsis-3 Definitions in Critically Ill Children [J]. JAMA Ped，2017，171（10）：352-354.
[10] Gulla K，Sachdev A，Gupta D，et al. Continuous renal replacement therapy in children with severe sepsis and multiorgan dysfunction -A pilot study on timing of initiation [J]. Indian J Crit Care Med，2015，19（10）：613-615.
[11] 罗运山，刘易林，邓霞梅，等.可溶性髓样细胞触发性受体1、降钙素原、C-反应蛋白在脓毒症中的临床价值[J].实用医学杂志，2016，32（17）：2861-2863.
[12] 王志文，刘占利，林争，等.脓毒症血流感染患儿血清C-反应蛋白、降钙素原水平变化及临床诊断分析[J].中华医院感染学杂志，2017，27（4）：919-922.
[13] 粱微波，庞晓清，刘晓青，等.动态监测血清可溶性髓样细胞触发受体1对脓毒症的诊断及预后评估价值[J].中国呼吸与危重监护杂志，2014，13（1）：53-57.
[14] 刘胜蕊，史晓峰，王兵，等.腹腔感染性脓毒症可溶性髓样细胞触发受体（sTREM-1）与Janus激酶-信号转导和转录激活因子（JAK/STAT）通路的关系[J].中华急诊医学杂志，2016，25（3）：314-319.
[15] 周光耀，张明，金玲湘，等.前降钙素原和C-反应蛋白对脓毒症早期诊断及预后评估的临床价值[J].中华医院感染学杂志，2014，24（4）：1027-1029.
[16] 潘定康，陈怿，段鹏凯，等.血清可溶性髓样细胞触发受体-1对重症脓毒症患者预后判断价值[J].第三军医大学学报，2016，38（8）：845-849.
[17] 任路，朱翠平，吴小惠.可溶性髓样细胞触发受体1检测在儿童脓毒症中的应用价值[J].广西医学，2015，37（11）：1595-1598.
[18] Zhao J，Lou X，Chen H，et al. Diagnostic value of decoy receptor 3 combined with procalcitonin and soluble urokinase-type plasminogen activator receptor for sepsis [J]. Cell Mol Biol Lett，2018，23（1）：90-93.
[19] Iskandar A，Arthamin MZ，Indriana K，et al. Comparison between presepsin and procalcitonin in early diagnosis of neonatal sepsis [J]. Mat-Fetl & Neo Med，2018，32（6）：1-11.
[20] El Haddad H，Chaftari AM，Hachem R，et al. Biomarkers of Sepsis and Bloodstream Infections：The Role of Procalcitonin and Proadrenomedullin with Emphasis in Patients with Cancer [J]. Clin Microbiol Infect，2018，24（5）：90-94.
[21] Aravena M. Terapia antimicrobiana guiada por procalcitonina en neonatos con sospecha de sepsis precoz [J]. Rev Chilena Infectol，2017，34（5）：522-524.
[22] Safiri S，Ayubi E，Mansori K. Comments on procalcitonin for the early diagnosis of sepsis in burn patients：A retrospective study [J]. Burns，2018，44（4）：1017-1019.